Key points are not available for this paper at this time.
The purpose of this study was to quantify the prevalence and co-prevalence of common comorbidities of type 2 diabetes mellitus (T2DM). Literature search was conducted in PubMed for relevant articles published during the period from 2013 to 2023. Studies describing the prevalence rate of T2DM and its associated co-morbidities in INDIA in the past 10 years and the pharmaceutical antidiabetic treatment were identified. Out of 100 articles 10 studies conducted in India fulfilled the inclusion criteria regarding the prevalence rate of T2DM along with its associated co-morbidities. Studies revealed that comorbidity burden tended to increase in older age groups and was higher in men than women. Few studies demonstrated for the combination of hypertension (HTN) and hyperlipidaemia (67.5%), followed by overweight/obesity and HTN (66.0%), overweight/obesity and hyperlipidaemia (62.5%), HTN and chronic kidney disease (CKD) (22.4%), hyperlipidaemia and CKD (21.1%), HTN and cardiovascular disease (CVD) (20.2%), hyperlipidaemia and CVD (20.1%), overweight/obesity and CKD (19.1%) and overweight/obesity and CVD (17.0%). The most common conditions in patients with T2DM included HTN in 82.1%; overweight/obesity in 78.2%; hyperlipidaemia in 77.2%; CKD in 24.1%; and CVD in 21.6%. It was concluded from the study that the vast majority of patients with T2DM have multiple comorbidities. To ensure a comprehensive approach to patient management, the presence of multimorbidity should be considered in the context of clinical decision making.
Kiran et al. (Tue,) studied this question.